These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8292502)

  • 1. On the use of parenteral magnesium salts in the treatment of acute ischaemic heart disease: a brief review.
    Mass H; Santoni F; Pirazzi B
    Magnes Res; 1993 Sep; 6(3):275-89. PubMed ID: 8292502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnesium in coronary artery disease--is there evidence?].
    Kiss K; Stühlinger HG; Glogar HD; Smetana R
    Wien Med Wochenschr; 2000; 150(15-16):325-9. PubMed ID: 11105327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection: emerging pharmacotherapy.
    Gumina RJ; Jahangir A; Gross GJ; Terzic A
    Expert Opin Pharmacother; 2001 May; 2(5):739-52. PubMed ID: 11336619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia.
    Broadley KJ; Penson PE
    Auton Autacoid Pharmacol; 2004 Oct; 24(4):87-93. PubMed ID: 15595927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischaemic postconditioning: does cardioplegia influence protection?
    Maruyama Y; Chambers DJ
    Eur J Cardiothorac Surg; 2012 Sep; 42(3):530-9. PubMed ID: 22345279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on infarct size and on arrhythmias by controlling reflow after myocardial ischaemia in pigs.
    Sjaastad I; Grund F; Ilebekk A
    Acta Physiol Scand; 2000 Jul; 169(3):195-201. PubMed ID: 10886034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should magnesium therapy be considered for the treatment of coronary heart disease? I. A critical appraisal of current facts and hypotheses.
    Weiss M; Lasserre B
    Magnes Res; 1994 Jun; 7(2):135-44. PubMed ID: 7999528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sympathetic nervous system and ischaemic heart disease.
    Remme WJ
    Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischaemic heart disease: clinical improvement with metabolic approach.
    Ferrari R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V7-20. PubMed ID: 11206104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral magnesium sulphate restores regional contractile function in the post-ischaemic canine myocardium.
    Mass H; Santoni F; Feliciano L; Santiago O; Albino D; De Leon N; Sifonte M
    Magnes Res; 1994 Dec; 7(3-4):255-66. PubMed ID: 7786688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic disarrangement in ischemic heart disease and its therapeutic control.
    Ferrari R
    Rev Port Cardiol; 1998 Sep; 17(9):667-84. PubMed ID: 9834638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of magnesium against ischaemia-reperfusion injury through inhibition of P-selectin in rats.
    Ying SQ; Fang L; Xiang MX; Xu G; Shan J; Wang JA
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1234-9. PubMed ID: 17973860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of magnesium in myocardial preservation.
    Lareau S; Boyle AJ; Stewart LC; Deslauriers R; Hendry P; Keon WJ; Labow RS
    Magnes Res; 1995 Mar; 8(1):85-97. PubMed ID: 7669511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial changes of soluble endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor.
    Serebruany VL; Schlossberg ML; Edenbaum LR; Herzog WR; Gurbel PA
    Pharmacol Res; 1998 Sep; 38(3):165-72. PubMed ID: 9782065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification for magnesium therapy in acute ischaemic heart disease. Clinical and experimental studies.
    Rasmussen HS
    Dan Med Bull; 1993 Mar; 40(1):84-99. PubMed ID: 8472601
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cardiovascular pathology and magnesium].
    Maurat JP; Kantelip JP; Anguenot T; Platonoff N
    Therapie; 1993; 48(6):599-607. PubMed ID: 8091345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature.
    Shechter M; Kaplinsky E; Rabinowitz B
    Arch Intern Med; 1992 Nov; 152(11):2189-96. PubMed ID: 1444677
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of magnesium in cardiovascular diseases.
    Kolte D; Vijayaraghavan K; Khera S; Sica DA; Frishman WH
    Cardiol Rev; 2014; 22(4):182-92. PubMed ID: 24896250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.